ATAI:NASDAQ
AtaiBeckley Inc
$४.२०
arrow_upward
+१.५७%(+०.०६५) 1D
$४.१८
arrow_downward
-०.४८% (-०.०२०)bedtimeAfter hours
Closed: ४ मे, ४:००:०१ PM [GMT]-४ · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | किंमत | बदल | % बदल |
|---|
insights_autoATAI साठी टॉप इनसाइट जनरेट करत आहे...
उघडा
$४.११
उच्च
$४.२८
कमी
$४.०४
मार्केट कॅप
१.५४ अब्ज
सरासरी उलाढाल
६५.८७ लाख
उलाढाल
५८.८८ लाख
५२ आठवड्यांतील उच्चांक
$६.७२
५२ आठवड्यांतील नीचांक
$१.२९
EPS
-$२.९१
बीटा
१.५९
थकित शेअर
३६.६९ कोटी
कर्मचाऱ्यांची संख्या
९९
बातम्यांच्या स्टोरी
संपूर्ण वेबवरील स्रोतांकडून
प्रोफाइल
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine.
In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff.
Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
AtaiBeckley Inc बद्दल
AI आशयामध्ये चुका असू शकतात. अधिक जाणून घ्या